Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: Correlation with other biologic factors

Cancer

Volumn 87, Issue 4, 1999, Pages 224-230

  Bozzetti, Cecilia ^a,b   Nizzoli, Rita ^a   Naldi, Nadia ^a   Guazzi, Annamaria ^a   Camisa, Roberta ^a   Bella, Maria Angela ^a   Cocconi, Giorgio ^a  

^a Ospedale di Parma   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Breast carcinoma; Correlation; Fine needle aspiration; Immunocytochemistry

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CELL DEATH; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033603776     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990825)87:4<224::AID-CNCR10>3.0.CO;2-5     Document Type: Article

References (39)

1. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is a inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
2. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
3. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83:5214-8.
4. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
5. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2:275-80.
6. Dive C, Evans CA, Whetton AD. Induction of apoptosis: new targets for cancer chemotherapy. Semin Cancer Biol 1992;3: 417-27.
7. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
8. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathologic correlates, with particular reference to estrogen receptor status. Virchows Arch 1994;424:47-51.
9. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998;82:1296-302.
10. Nathan B, Anbazhagan R, Dyer M, Ebbs SR, Jayatilake H, Gusterson BA. Expression of bcl-2-like immunoreactivity in the normal breast and in breast cancer. Breast 1993;2:134-7.
11. Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl-2 immunoreactiviry in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994;145:535-9.
12. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
13. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 1994;30:1663-9.
14. Gee JMW, Robertson JFR, Ellis IO, Willsher P, McClelland RA, Hoyle HB, et al. Immunocytochemical localization of Bcl-2 protein in human breast cancer and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619-28.
15. Gasparini G, Barbareschi M, Doglioni C, Dalla Palma P, Mauri FA, Boracchi P, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1:189-98.
16. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-60.
17. Van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, et al. Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996;74:78-85.
18. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox F, et al. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 1996;27:1149-55.
19. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut MN, et al. Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas. Br J Cancer 1997;76:340-6.
20. Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, et al. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997;44:65-74.
21. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
22. van Slooten HJ, van de Vijver MJ, van de Velde CJH, van Dierendonck JH. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 1998;77:789-96.
23. Sierra A, Castellsague X, Coll T, Manas S, Escobedo A, Moreno A, et al. Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas. Int J Cancer 1998;79:103-10.
24. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, et al. Bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J Clin Oncol 1998;16:2025-31.
25. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3:593-600.
26. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
27. Troncone G, Zeppa P, Vetrani A, D'Arcangelo A, Fulciniti F, De Divitiis B, et al. Bcl-2 protein in breast cancer cells obtained by fine needle aspiration (FNA): a preliminary report. Cytopathology 1995;6:219-25.
28. Franzèn F, Zajicek J. Aspiration biopsy in diagnosis of palpable lesions of the breast: critical review of 3479 consecutive biopsies. Acta Radiol 1968;7:241-62.
29. Kline TS, Jaski L, Neal HS. Fine needle aspiration of breast: diagnosis and pitfalls. Cancer 1979;44:1458-64.
30. Ljung BM, Chew K, Deng G, Matsumura K, Waldman F, Smith H. Fine needle aspiration techniques for the characterization of breast cancers. Cancer 1994;74:1000-5.
31. Bozzetti C, Nizzoli R, Naldi N, Manotti L, Savoldi L, Camisa R, et al. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma. Breast Cancer Res Treat 1994;32:221-8.
32. Zajicek J. Sampling of cells from human tumours by aspiration biopsy for diagnosis and research. Eur J Cancer 1965;1: 253-8.
33. Bozzetti C, Nizzoli R, Naldi N, Guazzi A, Camisa R, Manotti L, et al. Nuclear grading and flow cytometric DNA pattern in fine-needle aspirates of primary breast cancer. Diagn Cytopathol 1996;15:116-20.
34. Sabourin JC, Martin A, Baruch J, True JB, Compel A, Poitout P. bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994;59:1-6.
35. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-7.
36. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
37. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
38. Dabbs DJ. Role of nuclear grading of breast carcinomas in fine needle aspiration specimens. Acta Cytol 1993;37: 361-6.
39. Robinson IA, McKee G, Nicholson A, D'Arcy J, Jackson PA, Cook MG, et al. Prognostic value of cytologic grading of fine-needle aspirates from breast carcinomas. Lancet 1994; 343:947-9.